You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Ideally, we should account for WGD (baseline is 4 copies) when analyzing hyperploid tumors (e.g. TNBC5), which should lead to better model fit and prediction stability
The text was updated successfully, but these errors were encountered:
Isn't the baseline usually at three copies because of fitness? I have a cancer with 70% of samples with whole genome duplication and genome ploidy from PURPLE is rarely near four but often close to three, so I am looking forward to this enhancement!
Whereas chromosome losses are rarely tolerated in diploid cells, they occur frequently in tetraploid cells and can promote cancer formation.
Isn't the baseline usually at three copies because of fitness? I have a cancer with 70% of samples with whole genome duplication and genome ploidy from PURPLE is rarely near four but often close to three, so I am looking forward to this enhancement!
Right, although tumors that have ploidy near 3 should be ok unless no diploid regions are available anywhere on the genome. The issue only arises when the lowest (in copy number) balanced segments are 4 copies.
I noticed that non-WGD samples have near-perfect agreement to whole genome sequencing (PURPLE) but not WGD.
It seems implausible that all of a sample's arms would be lost or gained rather than a mix. Sample IDs ending in Bulk are WGS.
Ideally, we should account for WGD (baseline is 4 copies) when analyzing hyperploid tumors (e.g. TNBC5), which should lead to better model fit and prediction stability
The text was updated successfully, but these errors were encountered: